| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.29 | 9e-13 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.24 | 7e-11 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.23 | 8e-10 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-09 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.23 | 6e-09 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.23 | 9e-09 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.23 | 1e-08 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.22 | 3e-08 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.19 | 1e-07 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.2 | 1e-07 |